Storb R. HSCT: Historical Perspective. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Cham (CH): Springer International Publishing; 2019. p. 3–9.
Google Scholar
Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant. 2011;46(12):1495–502.
PubMed
CAS
Google Scholar
Pagliuca S, Michonneau D, de Fontbrune FS, del Galy AS, Xhaard A, Robin M, et al. Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Adv. 2019;3(15):2424–35.
PubMed
PubMed Central
Google Scholar
Carreras E, Palomo M, Ricart MD, Martínez-Sánchez J, on behalf of the Barcelona Endothelium Team. Vascular endothelial syndromes after HCT: 2020 update. Bone Marrow Transplant. 2020;55(10):1885–7.
PubMed
Google Scholar
Rondon G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, et al. Impact of fluid overload as new toxicity category on hematopoietic stem cell transplantation outcomes. Biol Blood Marrow Transplant. 2017;23(12):2166–71.
PubMed
PubMed Central
Google Scholar
Castillo P, Voigt K, Crockett C, Stout JT, Krance R, Naik S. Purtscher-like retinopathy: a rare presentation of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Pediatr Transplant. 2019;23(2):e13344.
PubMed
Google Scholar
Dvorak CC, Higham C, Shimano KA. Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management. Front Pediatr. 2019;7:133.
PubMed
PubMed Central
Google Scholar
Postalcioglu M, Kim HT, Obut F, Yilmam OA, Yang J, Byun BC, et al. Impact of thrombotic microangiopathy on renal outcomes and survival after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(11):2344–53.
PubMed
PubMed Central
Google Scholar
Gulla KC, Gupta K, Krarup A, Gal P, Schwaeble WJ, Sim RB, et al. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology. 2010;129(4):482–95.
PubMed
PubMed Central
CAS
Google Scholar
Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9(10):1057–69.
PubMed
PubMed Central
CAS
Google Scholar
Mai J, Virtue A, Shen J, Wang H, Yang X-F. An evolving new paradigm: endothelial cells—conditional innate immune cells. J Hematol Oncol. 2013;6(1):61.
PubMed
PubMed Central
Google Scholar
Hildebrandt GC, Chao N. Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation. Br J Haematol. 2020;190(4):508–19.
PubMed
PubMed Central
Google Scholar
Engin A. Endothelial dysfunction in obesity. In: Engin AB, Engin A, editors. Obesity and lipotoxicity. Cham: Springer International Publishing; 2017. p. 345–79.
Google Scholar
Saeid G, Lars E, Ismail L. Smoking and endothelial dysfunction. Curr Vasc Pharmacol. 2020;18(1):1–11.
Google Scholar
Khosla J, Yeh AC, Spitzer TR, Dey BR. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. Bone Marrow Transplant. 2018;53(2):129–37.
PubMed
CAS
Google Scholar
Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2018;53(2):138–45.
PubMed
CAS
Google Scholar
Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906–12.
PubMed
PubMed Central
CAS
Google Scholar
Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;28(5):425–34.
PubMed
CAS
Google Scholar
Afessa B, Tefferi A, Litzow MR, Krowka MJ, Wylam ME, Peters SG. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med. 2002;166(5):641–5.
PubMed
Google Scholar
Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, et al. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: Blood and Marrow Transplant Clinical Trials Network protocol. Biol Blood Marrow Transplant. 2014;20(6):858–64.
PubMed
PubMed Central
CAS
Google Scholar
Spitzer TR. Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50(4):469–75.
PubMed
CAS
Google Scholar
Lucchini G, Willasch AM, Daniel J, Soerensen J, Jarisch A, Bakhtiar S, et al. Epidemiology, risk factors, and prognosis of capillary leak syndrome in pediatric recipients of stem cell transplants: a retrospective single-center cohort study. Pediatr Transplant. 2016;20(8):1132–6.
PubMed
Google Scholar
Ghimire S, Weber D, Mavin E, Wang XN, Dickinson AM, Holler E. Pathophysiology of GvHD and other HSCT-related major complications. Front Immunol. 2017;8:79.
PubMed
PubMed Central
Google Scholar
Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, et al. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 2020;135(13):1049–57.
PubMed
PubMed Central
Google Scholar
Rotz SJ, Dandoy CE, Davies SM. ST2 and endothelial injury as a link between GVHD and microangiopathy. N Engl J Med. 2017;376(12):1189–90.
PubMed
Google Scholar
Gavriilaki E, Chrysanthopoulou A, Sakellari I, Batsis I, Mallouri D, Touloumenidou T, et al. Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy. Thromb Haemost. 2019;119(9):1433–40.
PubMed
Google Scholar
Schoettler M, Lehmann LE, Margossian S, Lee M, Kean LS, Kao PC, et al. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort. Blood Adv. 2020;4(11):2536–47.
PubMed
PubMed Central
CAS
Google Scholar
Dandoy CE, Rotz SR, Alonso PB, Lane A, Higham C, Dvorak CC, et al. Incidence and outcomes of patients with thrombotic microangiopathy after transplant: results of prospective screening through a multi-institutional collaborative. Biol Blood Marrow Transplant. 2020;26(3 Supplement):S92.
Google Scholar
Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124(4):645–53.
PubMed
PubMed Central
CAS
Google Scholar
Ye Y, Zheng W, Wang J, Hu Y, Luo Y, Tan Y, et al. Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study. Hematol Oncol. 2017;35(4):821–7.
PubMed
CAS
Google Scholar
Zeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, et al. Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant. 2017;52(10):1399–405.
PubMed
CAS
Google Scholar
Sridharan M, Go RS, Shah MV, Litzow MR, Hogan WJ, Alkhateeb HB. Incidence and mortality outcomes in allogeneic transplant-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2018;24(3):S329–30.
Google Scholar
Li A, Wu Q, Davis C, Kirtane KS, Pham PD, Sorror ML, et al. Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal. Biol Blood Marrow Transplant. 2019;25(3):570–6.
PubMed
Google Scholar
Kraft S, Bollinger N, Bodenmann B, Heim D, Bucher C, Lengerke C, et al. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. Bone Marrow Transplant. 2019;54(4):540–8.
PubMed
Google Scholar
Sakellari I, Gavriilaki E, Boussiou Z, Batsis I, Mallouri D, Constantinou V, et al. Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases. Hematol Oncol. 2017;35(4):932–4.
PubMed
Google Scholar
Wall SA, Zhao Q, Yearsley M, Blower L, Agyeman A, Ranganathan P, et al. Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. Blood Adv. 2018;2(20):2619–28.
PubMed
PubMed Central
CAS
Google Scholar
Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al. Blood and Marrow Transplant Clinical Trials Network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(8):571–5.
PubMed
Google Scholar
Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92(1):95–100.
PubMed
Google Scholar
Cho BS, Yahng SA, Lee SE, Eom KS, Kim YJ, Kim HJ, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;90(8):918–26.
PubMed
CAS
Google Scholar
Shayani S, Palmer J, Stiller T, Liu X, Thomas SH, Khuu T, et al. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013;19(2):298–304.
PubMed
Google Scholar
Uderzo CC, Jodele S, Missiry ME, Ciceri F, Busca A, Bacigalupo A, et al. Transplant-associated thrombotic microangiopathy (TA-TMA) and consensus based diagnostic and therapeutic recommendations: which TA-TMA patients to treat and when? J Bone Marrow Res. 2014;2:152.
Google Scholar
Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I—molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
PubMed
PubMed Central
Google Scholar
Eriksson O, Mohlin C, Nilsson B, Ekdahl KN. The human platelet as an innate immune cell: interactions between activated platelets and the complement system. Front Immunol. 2019;10:1590.
PubMed
PubMed Central
CAS
Google Scholar
Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12(7):383–401.
PubMed
PubMed Central
CAS
Google Scholar
Bohlson SS, Garred P, Kemper C, Tenner AJ. Complement nomenclature-deconvoluted. Front Immunol. 2019;10:1308.
PubMed
PubMed Central
CAS
Google Scholar
Buerke M, Prüfer D, Dahm M, Oelert H, Meyer J, Darius H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J Pharmacol Exp Ther. 1998;286(1):429–38.
PubMed
CAS
Google Scholar
Weiser MR, Williams JP, Moore FD Jr, Kobzik L, Ma M, Hechtman HB, et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med. 1996;183(5):2343–8.
PubMed
CAS
Google Scholar
Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol. 2000;156(5):1549–56.
PubMed
PubMed Central
CAS
Google Scholar
Hart ML, Ceonzo KA, Shaffer LA, Takahashi K, Rother RP, Reenstra WR, et al. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol. 2005;174(10):6373–80.
PubMed
CAS
Google Scholar
Gorsuch WB, Chrysanthou E, Schwaeble WJ, Stahl GL. The complement system in ischemia-reperfusion injuries. Immunobiology. 2012;217(11):1026–33.
PubMed
PubMed Central
CAS
Google Scholar
Farrar CA, Asgari E, Schwaeble WJ, Sacks SH. Which pathways trigger the role of complement in ischaemia/reperfusion injury? Front Immunol. 2012;3:341.
PubMed
PubMed Central
Google Scholar
Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018;14(1):26–47.
PubMed
CAS
Google Scholar
Garred P, Genster N, Pilely K, Bayarri-Olmos R, Rosbjerg A, Ma YJ, et al. A journey through the lectin pathway of complement-MBL and beyond. Immunol Rev. 2016;274(1):74–97.
PubMed
CAS
Google Scholar
Degn SE, Kjaer TR, Kidmose RT, Jensen L, Hansen AG, Tekin M, et al. Complement activation by ligand-driven juxtaposition of discrete pattern recognition complexes. Proc Natl Acad Sci. 2014;111(37):13445–50.
PubMed
PubMed Central
CAS
Google Scholar
Matsushita M, Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med. 1992;176(6):1497–502.
PubMed
CAS
Google Scholar
Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature. 1997;386(6624):506–10.
PubMed
CAS
Google Scholar
Dahl MR, Thiel S, Matsushita M, Fujita T, Willis AC, Christensen T, et al. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity. 2001;15(1):127–35.
PubMed
CAS
Google Scholar
Schwaeble WJ, Lynch NJ, Clark JE, Marber M, Samani NJ, Ali YM, et al. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci. 2011;108(18):7523–8.
PubMed
PubMed Central
CAS
Google Scholar
Dobo J, Schroeder V, Jenny L, Cervenak L, Zavodszky P, Gal P. Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation. Mol Immunol. 2014;61(2):69–78.
PubMed
CAS
Google Scholar
Dobo J, Pal G, Cervenak L, Gal P. The emerging roles of mannose-binding lectin-associated serine proteases (MASPs) in the lectin pathway of complement and beyond. Immunol Rev. 2016;274(1):98–111.
PubMed
CAS
Google Scholar
Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J Immunol. 2000;165(5):2637–42.
PubMed
CAS
Google Scholar
Oroszlan G, Kortvely E, Szakacs D, Kocsis A, Dammeier S, Zeck A, et al. MASP-1 and MASP-2 do not activate pro-Factor D in resting human blood, whereas MASP-3 is a potential activator: kinetic analysis involving specific MASP-1 and MASP-2 inhibitors. J Immunol. 2016;196(2):857–65.
PubMed
CAS
Google Scholar
Dobó J, Szakács D, Oroszlán G, Kortvely E, Kiss B, Boros E, et al. MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked. Sci Rep. 2016;6:31877.
PubMed
PubMed Central
Google Scholar
Iwaki D, Kanno K, Takahashi M, Endo Y, Matsushita M, Fujita T. The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway. J Immunol. 2011;187(7):3751–8.
PubMed
CAS
Google Scholar
Pihl R, Jensen L, Hansen AG, Thogersen IB, Andres S, Dagnaes-Hansen F, et al. Analysis of factor D isoforms in Malpuech-Michels-Mingarelli-Carnevale patients highlights the role of MASP-3 as a maturase in the alternative pathway of complement. J Immunol. 2017;199:2158–70.
CAS
Google Scholar
Hayashi M, Machida T, Ishida Y, Ogata Y, Omori T, Takasumi M, et al. Cutting edge: role of MASP-3 in the physiological activation of Factor D of the alternative complement pathway. J Immunol. 2019;203(6):1411–6.
PubMed
CAS
Google Scholar
Dobo J, Kocsis A, Gal P. Be on target: strategies of targeting alternative and lectin pathway components in complement-mediated diseases. Front Immunol. 2018;9:1851.
PubMed
PubMed Central
Google Scholar
Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol. 2007;179(4):2600.
PubMed
CAS
Google Scholar
Ma YJ, Lee BL, Garred P. An overview of the synergy and crosstalk between pentraxins and collectins/ficolins: their functional relevance in complement activation. Exp Mol Med. 2017;49(4):e320.
PubMed
PubMed Central
CAS
Google Scholar
Krarup A, Wallis R, Presanis JS, Gal P, Sim RB. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE. 2007;2(7):e623.
PubMed
PubMed Central
Google Scholar
Demopulos GA, Dudler T, Nilsson B, inventors; Omeros Corporation, assignee. Compositions and methods of inhibiting MASP-2 for the treatment of various thrombotic diseases and disorders. Patent WO 2019/246367 A1. 2019.
Kozarcanin H, Lood C, Munthe-Fog L, Sandholm K, Hamad OA, Bengtsson AA, et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. J Thromb Haemost. 2016;14(3):531–45.
PubMed
CAS
Google Scholar
Monsinjon T, Richard V, Fontaine M. Complement and its implications in cardiac ischemia/reperfusion: strategies to inhibit complement. Fundam Clin Pharmacol. 2001;15(5):293–306.
PubMed
CAS
Google Scholar
Castellano G, Melchiorre R, Loverre A, Ditonno P, Montinaro V, Rossini M, et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol. 2010;176(4):1648–59.
PubMed
PubMed Central
Google Scholar
Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, et al. Predominant role for C5b–9 in renal ischemia/reperfusion injury. J Clin Invest. 2000;105(10):1363–71.
PubMed
PubMed Central
CAS
Google Scholar
Farrar CA, Tran D, Li K, Wu W, Peng Q, Schwaeble W, et al. Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury. J Clin Invest. 2016;126(5):1911–25.
PubMed
PubMed Central
Google Scholar
Alghadban S, Kenawy HI, Dudler T, Schwaeble WJ, Brunskill NJ. Absence of the lectin activation pathway of complement ameliorates proteinuria-induced renal injury. Front Immunol. 2019;10(2238):2238.
PubMed
PubMed Central
CAS
Google Scholar
Nauser CL, Howard MC, Fanelli G, Farrar CA, Sacks S. Collectin-11 (CL-11) is a major sentinel at epithelial surfaces and key pattern recognition molecule in complement-mediated ischaemic injury. Front Immunol. 2023;2018(9):2023.
Google Scholar
Orsini F, Chrysanthou E, Dudler T, Cummings WJ, Takahashi M, Fujita T, et al. Mannan binding lectin-associated serine protease-2 (MASP-2) critically contributes to post-ischemic brain injury independent of MASP-1. J Neuroinflammation. 2016;13(1):213.
PubMed
PubMed Central
Google Scholar
Cervera A, Planas AM, Justicia C, Urra X, Jensenius JC, Torres F, et al. Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS ONE. 2010;5(2):e8433.
PubMed
PubMed Central
Google Scholar
Osthoff M, Walder B, Delhumeau C, Trendelenburg M, Turck N. Association of lectin pathway protein levels and genetic variants early after injury with outcomes after severe traumatic brain injury: a prospective cohort study. J Neurotrauma. 2017;34(17):2560–6.
PubMed
Google Scholar
Fust G, Munthe-Fog L, Illes Z, Szeplaki G, Molnar T, Pusch G, et al. Low ficolin-3 levels in early follow-up serum samples are associated with the severity and unfavorable outcome of acute ischemic stroke. J Neuroinflamm. 2011;8:185.
CAS
Google Scholar
Zanier ER, Zangari R, Munthe-Fog L, Hein E, Zoerle T, Conte V, et al. Ficolin-3-mediated lectin complement pathway activation in patients with subarachnoid hemorrhage. Neurology. 2014;82(2):126–34.
PubMed
CAS
Google Scholar
Song FY, Wu MH, Zhu LH, Zhang ZQ, Qi QD, Lou CL. Elevated serum mannose-binding lectin levels are associated with poor outcome after acute ischemic stroke in patients with type 2 diabetes. Mol Neurobiol. 2015;52(3):1330–40.
PubMed
CAS
Google Scholar
Zhang ZG, Wang C, Wang J, Zhang Z, Yang YL, Gao L, et al. Prognostic value of mannose-binding lectin: 90-day outcome in patients with acute ischemic stroke. Mol Neurobiol. 2015;51(1):230–9.
PubMed
CAS
Google Scholar
Clark JE, Dudler T, Marber MS, Schwaeble W. Cardioprotection by an anti-MASP-2 antibody in a murine model of myocardial infarction. Open Heart. 2018;5(1):e000652.
PubMed
PubMed Central
Google Scholar
Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.
PubMed
PubMed Central
CAS
Google Scholar
Ali YM, Ferrari M, Lynch NJ, Yaseen S, Dudler T, Gragerov S, et al. Lectin pathway mediates complement activation by SARS-CoV-2 proteins. Front Immunol. 2021. https://doi.org/10.3389/fimmu.2021.714511.
Article
PubMed
PubMed Central
Google Scholar
Gao T, Hu M, Zhang X, Li H, Zhu L, Liu H, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv. 2020. https://doi.org/10.1101/2020.03.29.20041962.
Article
PubMed
PubMed Central
Google Scholar
Gavriilaki E, Brodsky RA. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily. Br J Haematol. 2020;189(6):e227–30.
PubMed
CAS
Google Scholar
Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020;215:108450.
PubMed
PubMed Central
CAS
Google Scholar
Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040–7.
PubMed
CAS
Google Scholar
Rambaldi A, Gritti G, Mico MC, Frigeni M, Borleri G, Salvi A, et al. Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology. 2020;225(6):152001.
PubMed
PubMed Central
CAS
Google Scholar
Alexion provides update on phase 3 study of ULTOMIRIS® (ravulizumab-cwvz) in hospitalized patients with severe COVID-19. https://ir.alexion.com/news-releases/news-release-details/alexion-provides-update-phase-3-study-ultomirisr-ravulizumab. Accessed 11 Feb 2021.
Staidson links with Pivotal to test BDB-001 in severe COVID-19 patients. https://www.thepharmaletter.com/article/staidson-links-with-pivotal-to-test-bdb-001-in-severe-covid-19-patients. Accessed 29 Jan 2021.
A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE). https://clinicaltrials.gov/ct2/show/NCT04395456. Accessed 12 March 2021.
Apellis Provides Update on APL-9 for Severe COVID-19. https://investors.apellis.com/news-releases/news-release-details/apellis-provides-update-apl-9-severe-covid-19. Accessed 2 Apr 2021.
Gavriilaki E, Sakellari I, Anagnostopoulos A, Brodsky RA. Transplant-associated thrombotic microangiopathy: opening Pandora’s box. Bone Marrow Transplant. 2017;52(10):1355–60.
PubMed
CAS
Google Scholar
Horvath O, Kallay K, Csuka D, Mezo B, Sinkovits G, Kassa C, et al. Early increase in complement terminal pathway activation marker sC5b-9 is predictive for the development of thrombotic microangiopathy after stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(5):989–96.
PubMed
CAS
Google Scholar
Qi J, Wang J, Chen J, Su J, Tang Y, Wu X, et al. Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation. Ann Hematol. 2017;96(11):1849–55.
PubMed
PubMed Central
CAS
Google Scholar
Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(2):307–15.
PubMed
CAS
Google Scholar
Gavriilaki E, Touloumenidou T, Sakellari I, Batsis I, Mallouri D, Psomopoulos F, et al. Pretransplant genetic susceptibility: clinical relevance in transplant-associated thrombotic microangiopathy. Thromb Haemost. 2020;120(4):638–46.
PubMed
Google Scholar
Rotz SJ, Luebbering N, Dixon BP, Gavriilaki E, Brodsky RA, Dandoy CE, et al. In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy. Blood Adv. 2017;1(20):1632–4.
PubMed
PubMed Central
CAS
Google Scholar
Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood. 2016;127(8):989–96.
PubMed
PubMed Central
CAS
Google Scholar
Jodele S, Medvedovic M, Luebbering N, Chen J, Dandoy CE, Laskin BL, et al. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv. 2020;4(6):1166–77.
PubMed
PubMed Central
CAS
Google Scholar
Jodele S, Dandoy CE, Myers KC, El-Bietar J, Nelson A, Wallace G, et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci. 2016;54(2):181–90.
PubMed
PubMed Central
Google Scholar
Rossoff JE, Schneiderman J, Chaudhury S, Arva NC. Diagnostic utility of complement immunohistochemical studies in post-stem cell transplant intestinal thrombotic microangiopathy: case report. J Pediatr Hematol Oncol. 2017;39(4):282–6.
PubMed
Google Scholar
Jodele S. Complement in pathophysiology and treatment of transplant-associated thrombotic microangiopathies. Semin Hematol. 2018;55(3):159–66.
PubMed
Google Scholar
Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, et al. Modified Ham test for atypical hemolytic uremic syndrome. Blood. 2015;125(23):3637–46.
PubMed
PubMed Central
CAS
Google Scholar
Elhadad S, Chapin J, Copertino D, Van Besien K, Ahamed J, Laurence J. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol. 2020;203(1):96–104.
PubMed
PubMed Central
Google Scholar
Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529–39.
PubMed
PubMed Central
CAS
Google Scholar
Rowan CM, Pike F, Cooke KR, Krance R, Carpenter PA, Duncan C, et al. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups. Blood. 2020;135(17):1428–37.
PubMed
PubMed Central
Google Scholar
Sampson ME, Lane A, Lake KE, Luebbering N, Dandoy CE, Davies SM. Ann Arbor Score predicts thrombotic microangiopathy but not graft-versus-host disease in pediatric bone marrow transplant recipients. Biol Blood Marrow Transplant. 2019;25:S230–1.
Google Scholar
Luft T, Benner A, Terzer T, Jodele S, Dandoy CE, Storb R, et al. EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant. 2020;55(3):553–61.
PubMed
CAS
Google Scholar
Gavriilaki E, Sakellari I, Chatziconstantinou T, Mallouri D, Batsis I, Vardi A, et al. EASIX is strongly associated with complement activation and overall survival in adult allogeneic hematopoietic cell transplantation recipients. Blood. 2019;134(Supplement 1):4520.
Google Scholar
Gavriilaki E, Sakellari I, Chatzikonstantinou T, Mallouri D, Batsis I, Vardi A, et al. Endothelial and complement activation as predictors of survival in adult allogeneic hematopoietic cell transplantation. HemaSphere. 2021;5(1):e487.
PubMed
Google Scholar
El-Bietar J, Warren M, Dandoy C, Myers KC, Lane A, Wallace G, et al. Histologic features of intestinal thrombotic microangiopathy in pediatric and young adult patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(11):1994–2001.
PubMed
PubMed Central
Google Scholar
Gavriilaki E, Sakellari I, Karafoulidou I, Pasteli N, Batsis I, Mallouri D, et al. Intestinal thrombotic microangiopathy: a distinct entity in the spectrum of graft-versus-host disease. Int J Hematol. 2019;110(5):529–32.
PubMed
CAS
Google Scholar
Jodele S, Laskin BL, Goebel J, Khoury JC, Pinkard SL, Carey PM, et al. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? Transfusion. 2013;53(3):661–7.
PubMed
CAS
Google Scholar
Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2015;35(5):421–47.
PubMed
Google Scholar
Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest. 2020;130(5):2152–63.
PubMed
PubMed Central
CAS
Google Scholar
Defitelio prescribing information. https://pp.jazzpharma.com/pi/defitelio.en.USPI.pdf. Accessed 16 Mar 2021.
Defitelio EPAR product information. https://www.ema.europa.eu/en/documents/product-information/defitelio-epar-product-information_en.pdf. Accessed 16 Mar 2021.
Uderzo C, Fumagalli M, De Lorenzo P, Busca A, Vassallo E, Bonanomi S, et al. Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation. Bone Marrow Transplant. 2000;26(9):1005–9.
PubMed
CAS
Google Scholar
Corti P, Uderzo C, Tagliabue A, Della Volpe A, Annaloro C, Tagliaferri E, et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2002;29(6):542–3.
PubMed
CAS
Google Scholar
Uderzo C, Bonanomi S, Busca A, Renoldi M, Ferrari P, Iacobelli M, et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation. 2006;82(5):638–44.
PubMed
Google Scholar
Martínez-Muñoz ME, Forés R, Lario A, Bautista G, Bueno JL, de Miguel C, et al. Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy. Bone Marrow Transplant. 2019;54(1):142–5.
PubMed
Google Scholar
Yeates L, Slatter MA, Bonanomi S, Lim F, Ong SY, Dalissier A, et al. Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant. 2017;52(5):762–4.
PubMed
CAS
Google Scholar
Devadas SK, Toshniwal M, Bagal B, Khattry N. Successful treatment of transplant associated thrombotic microangiopathy (TA-TMA) with low dose defibrotide. Indian J Hematol Blood Transfus. 2018;34(3):469–73.
PubMed
Google Scholar
Gavriilaki E, de Latour RP, Risitano AM. Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond. Blood. 2021. https://doi.org/10.1182/blood.2021012860.
Article
PubMed
Google Scholar
Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33(17–18):1389–401.
PubMed
CAS
Google Scholar
Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014;20(4):518–25.
PubMed
CAS
Google Scholar
Sevindik OG, Alacacioglu I, Katgi A, Solmaz SM, Acar C, Piskin O, et al. Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation. Case Rep Hematol. 2015;2015:425410.
PubMed
PubMed Central
Google Scholar
Fernandez C, Lario A, Fores R, Cabrera R. Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease. Hematol Rep. 2015;7(4):6107.
PubMed
PubMed Central
Google Scholar
de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation. 2015;99(9):1953–9.
PubMed
Google Scholar
Bohl SR, Kuchenbauer F, von Harsdorf S, Kloevekorn N, Schönsteiner SS, Rouhi A, et al. Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy. Biol Blood Marrow Transplant. 2017;23(12):2172–7.
PubMed
CAS
Google Scholar
Gavriilaki E, Sakellari I, Bousiou Z, Batsis I, Mallouri D, Masmanidou M, et al. Complement inhibition with eculizumab in adult transplant-associated thrombotic microangiopathy: opening the Pandora’s box. Transplant Cell Ther. 2021;27(3 Supplement):S270–1.
Google Scholar
Scordo M, Giralt S. Compliments to complement blockade for TA-TMA. Blood. 2020;135(13):981–3.
PubMed
CAS
Google Scholar
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2020;97(6):1287–96.
PubMed
CAS
Google Scholar
Lee JW, de Fontbrune FS, Lee WLL, Pessoa V, Gualandro S, Füreder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–9.
PubMed
PubMed Central
CAS
Google Scholar
Ravulizumab in thrombotic microangiopathy after hematopoietic stem cell transplant. https://clinicaltrials.gov/ct2/show/NCT04543591. Accessed 16 Nov 2021.
Study of ravulizumab in pediatric participants with HSCT-TMA. https://clinicaltrials.gov/ct2/show/NCT04557735. Accessed 16 Nov 2021.
Akari Therapeutics. https://www.akaritx.com/2019/12/23/akari-therapeutics-announces-initiation-of-pivotal-phase-iii-trial-of-nomacopan-in-pediatric-hematopoietic-stem-cell-transplant-related-thrombotic-microangiopathy-hsct-tma-following-the-opening-of-i/. Accessed 5 May 2021.
Goodship THJ, Pinto F, Weston-Davies WH, Silva J, Nishimura J-I, Nunn MA, et al. Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv. 2017;1(16):1254–8.
PubMed
PubMed Central
CAS
Google Scholar
Nomacopan (rVA576) in transplant associated thrombotic microangiopathy. https://clinicaltrials.gov/ct2/show/NCT04784455. Accessed 16 Nov 2021.
van Emmerik LC, Kuijper EJ, Fijen CA, Dankert J, Thiel S. Binding of mannan-binding protein to various bacterial pathogens of meningitis. Clin Exp Immunol. 1994;97(3):411–6.
PubMed
PubMed Central
Google Scholar
Safety and efficacy study of OMS721 in patients with thrombotic microangiopathies. https://clinicaltrials.gov/ct2/show/NCT02222545. Accessed 16 Nov 2021.
Khaled SK, Boelens JJ, Cairo MS, Champlin R, Duarte RF, Giralt SA, et al. Narsoplimab (OMS721), a MASP-2 inhibitor, for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Transplant Cell Ther. 2021;27(3 Supplement):S24–6.
Google Scholar
de la Cámara R. Vaccinations. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Cham: Springer International Publishing; 2019. p. 207–19. https://doi.org/10.1007/978-3-030-02278-5_29.
Chapter
Google Scholar
Mahler MB, Taur Y, Jean R, Kernan NA, Prockop SE, Small TN. Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(1):145–9.
PubMed
CAS
Google Scholar
Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson A, et al. Terminal complement blockade after hematopoietic stem cell transplantation is safe without meningococcal vaccination. Biol Blood Marrow Transplant. 2016;22(7):1337–40.
PubMed
PubMed Central
Google Scholar
Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22(3):400–9.
PubMed
Google Scholar
Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, et al. Incidence, predictors, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26(3):529–39.
PubMed
CAS
Google Scholar
Senzolo M, Germani G, Cholongitas E, Burra P, Burroughs AK. Veno occlusive disease: update on clinical management. World J Gastroenterol. 2007;13(29):3918–24.
PubMed
PubMed Central
CAS
Google Scholar
Elbahlawan L, Srinivasan A, Morrison RR. A critical care and transplantation-based approach to acute respiratory failure after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant. 2016;22(4):617–26.
PubMed
Google Scholar
Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27(9):893–8.
PubMed
CAS
Google Scholar
Chang L, Frame D, Braun T, Gatza E, Hanauer DA, Zhao S, et al. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014;20(9):1407–17.
PubMed
PubMed Central
Google Scholar
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10.
PubMed
Google Scholar
Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53(11):1401–15.
PubMed
PubMed Central
Google Scholar
Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015;29(3):191–204.
PubMed
Google Scholar
Soliris prescribing information. https://alexion.com/Documents/Soliris_USPI.pdf. Accessed 5 May 2021.
Eculizumab to treat thrombotic microangiopathy/atypical hemolytic uremic syndrome-associated multiple organ dysfunction syndrome in hematopoietic stem cell transplant recipients. https://clinicaltrials.gov/ct2/show/NCT03518203. Accessed 16 Nov 2021.